StockEdge.com
  • Products
    • StockEdge Premium
    • StockEdge Pro
    • StockEdge Club
    • Compare Plans
StockEdge Blog
  • Trending Stocks
  • Insights
    • All
    • Business Houses
    • Markets themes
    • Stock Insights
    Zomato Shares

    Zomato Shares/Stock Analysis: Profile, Financials & Growth

    Aster DM Healthcare’s Spinoff of Gulf Hospitals – A Special Situation You Can’t Afford to Miss!

    Aster DM Healthcare’s Spinoff of Gulf Hospitals – A Special Situation You Can’t Afford to Miss!

    An image charging the electric vehicle from e-station and Text written on the right side

    India’s Top Electric Vehicle(EV) Stocks

    Top 5 Textile stocks

    Top 5 Textile Stocks in India: From Cotton to Cash

    multi-bagger stocks for 2025

    5 Multibagger Stocks to keep an eagle-eye for 2025

    Jindal Saw – Strong Earnings Momentum Ahead

    Jindal Saw – Strong Earnings Momentum Ahead

    Kirloskar Group- A Legacy of 134 Years

    Kirloskar Group- A Legacy of 134 Years

    renewable energy stocks in india

    Top Renewable Energy Stocks in India

    blue chip stocks

    Top 5 Blue Chip Stocks to Buy and Invest in 2023

  • Technical Analysis
    Chart Patterns – Holy grail of Stock Market Analysis

    Chart Patterns – Holy grail of Stock Market Analysis

    StockEdge Version Update : 9.0

    StockEdge Version Update : 9.0

    Beat the street with Sector Rotation Strategy

    Beat the street with Sector Rotation Strategy

    StockEdge Version Update 8.2

    StockEdge Version Update 8.2

    Derivative Analytics

    An Insightful Research Tool For Derivative Analytics

    Introducing Put-Call Ratio a Derivative Indicator in the Market

    Introducing Put-Call Ratio a Derivative Indicator in the Market

    A Powerful Technical Indicator Beta & Beta Scans

    A Powerful Technical Indicator Beta & Beta Scans

    Technical Analysis using Edge Charts

    Technical Analysis using Edge Charts

    adaptive relative strength and static relative strength scans

    What is Adaptive Relative Strength & Static Relative Strength Scans?

  • Fundamental Analysis
    • All
    • Cash Flow Ratios
    • Efficiency ratios
    • Growth Ratios
    • Liquidity Ratios
    • Return Ratios
    • Solvency ratios
    • Valuation Ratios
    high dividend paying stocks

    Identifying High Dividend Paying Stocks

    Understanding the Importance of creating Fundamental Scans

    Understanding the Importance of creating Fundamental Scans

    Using My Combination Scan to Identify best in an Industry

    Using My Combination Scan to Identify best in an Industry

    Cost Income ratio

    Cost to Income Ratio(%)

    Cost of Liability

    Cost of Liabilities (%)

    Operating Cost to Assets Ratio (%)

    Operating Cost to Assets Ratio (%)

  • StockEdge Tutorials
    Simplify stock market analysis with Edge Reports | StockEdge

    Simplify stock market analysis with Edge Reports | StockEdge

    StockEdge Club: An Exclusive Investors Hub & Analytics platform

    StockEdge Club: An Exclusive Investors Hub & Analytics platform

    FII/DII Data: Leading Indicators of Stock Market

    FII/DII Data: Leading Indicators of Stock Market

    Chart Patterns – Holy grail of Stock Market Analysis

    Chart Patterns – Holy grail of Stock Market Analysis

    StockEdge Version Update : 9.0

    StockEdge Version Update : 9.0

    Powerful Investment Themes for Retail Investors

    Powerful Investment Themes for Retail Investors

    Beat the street with Sector Rotation Strategy

    Beat the street with Sector Rotation Strategy

    StockEdge Version Update 8.3

    StockEdge Version Update 8.3

    StockEdge Version Update 8.2

    StockEdge Version Update 8.2

  • Mutual Fund
    Top 5 Mutual Funds for 2022 where you can start your SIP

    Top 5 Mutual Funds for 2022 where you can start your SIP

    What are Value Funds and its Advantages?

    What are Value Funds and its Advantages?

    thematic funds

    Thematic Funds : Everything you need to know

    Understanding Sector Funds and their Benefits to our Portfolio

    Understanding Sector Funds and their Benefits to our Portfolio

    Are Dividend Yield Funds a good option to invest in?

    Are Dividend Yield Funds a good option to invest in?

    What are Contra Funds and their advantages?

    What are Contra Funds and their advantages?

    Trending Tags

    No Result
    View All Result
    • Trending Stocks
    • Insights
      • All
      • Business Houses
      • Markets themes
      • Stock Insights
      Zomato Shares

      Zomato Shares/Stock Analysis: Profile, Financials & Growth

      Aster DM Healthcare’s Spinoff of Gulf Hospitals – A Special Situation You Can’t Afford to Miss!

      Aster DM Healthcare’s Spinoff of Gulf Hospitals – A Special Situation You Can’t Afford to Miss!

      An image charging the electric vehicle from e-station and Text written on the right side

      India’s Top Electric Vehicle(EV) Stocks

      Top 5 Textile stocks

      Top 5 Textile Stocks in India: From Cotton to Cash

      multi-bagger stocks for 2025

      5 Multibagger Stocks to keep an eagle-eye for 2025

      Jindal Saw – Strong Earnings Momentum Ahead

      Jindal Saw – Strong Earnings Momentum Ahead

      Kirloskar Group- A Legacy of 134 Years

      Kirloskar Group- A Legacy of 134 Years

      renewable energy stocks in india

      Top Renewable Energy Stocks in India

      blue chip stocks

      Top 5 Blue Chip Stocks to Buy and Invest in 2023

    • Technical Analysis
      Chart Patterns – Holy grail of Stock Market Analysis

      Chart Patterns – Holy grail of Stock Market Analysis

      StockEdge Version Update : 9.0

      StockEdge Version Update : 9.0

      Beat the street with Sector Rotation Strategy

      Beat the street with Sector Rotation Strategy

      StockEdge Version Update 8.2

      StockEdge Version Update 8.2

      Derivative Analytics

      An Insightful Research Tool For Derivative Analytics

      Introducing Put-Call Ratio a Derivative Indicator in the Market

      Introducing Put-Call Ratio a Derivative Indicator in the Market

      A Powerful Technical Indicator Beta & Beta Scans

      A Powerful Technical Indicator Beta & Beta Scans

      Technical Analysis using Edge Charts

      Technical Analysis using Edge Charts

      adaptive relative strength and static relative strength scans

      What is Adaptive Relative Strength & Static Relative Strength Scans?

    • Fundamental Analysis
      • All
      • Cash Flow Ratios
      • Efficiency ratios
      • Growth Ratios
      • Liquidity Ratios
      • Return Ratios
      • Solvency ratios
      • Valuation Ratios
      high dividend paying stocks

      Identifying High Dividend Paying Stocks

      Understanding the Importance of creating Fundamental Scans

      Understanding the Importance of creating Fundamental Scans

      Using My Combination Scan to Identify best in an Industry

      Using My Combination Scan to Identify best in an Industry

      Cost Income ratio

      Cost to Income Ratio(%)

      Cost of Liability

      Cost of Liabilities (%)

      Operating Cost to Assets Ratio (%)

      Operating Cost to Assets Ratio (%)

    • StockEdge Tutorials
      Simplify stock market analysis with Edge Reports | StockEdge

      Simplify stock market analysis with Edge Reports | StockEdge

      StockEdge Club: An Exclusive Investors Hub & Analytics platform

      StockEdge Club: An Exclusive Investors Hub & Analytics platform

      FII/DII Data: Leading Indicators of Stock Market

      FII/DII Data: Leading Indicators of Stock Market

      Chart Patterns – Holy grail of Stock Market Analysis

      Chart Patterns – Holy grail of Stock Market Analysis

      StockEdge Version Update : 9.0

      StockEdge Version Update : 9.0

      Powerful Investment Themes for Retail Investors

      Powerful Investment Themes for Retail Investors

      Beat the street with Sector Rotation Strategy

      Beat the street with Sector Rotation Strategy

      StockEdge Version Update 8.3

      StockEdge Version Update 8.3

      StockEdge Version Update 8.2

      StockEdge Version Update 8.2

    • Mutual Fund
      Top 5 Mutual Funds for 2022 where you can start your SIP

      Top 5 Mutual Funds for 2022 where you can start your SIP

      What are Value Funds and its Advantages?

      What are Value Funds and its Advantages?

      thematic funds

      Thematic Funds : Everything you need to know

      Understanding Sector Funds and their Benefits to our Portfolio

      Understanding Sector Funds and their Benefits to our Portfolio

      Are Dividend Yield Funds a good option to invest in?

      Are Dividend Yield Funds a good option to invest in?

      What are Contra Funds and their advantages?

      What are Contra Funds and their advantages?

      Trending Tags

      No Result
      View All Result
      StockEdge Blog
      Home Insights
      What’s up with Laurus Labs?

      What’s up with Laurus Labs?

      StockEdge by StockEdge
      November 24, 2021
      Reading Time: 6 mins read
      32.1k
      VIEWS
      Share on FacebookShare on TwitterShare On WhatsApp

      Table of Contents

      • The Story
      • How Laurus Labs is betting on CAR-T Cell Therapy, which is Revolutionizing Oncology!
          • Now what exactly ImmunoACT does?
      • But then why is Laurus Labs investing into Immuno ACT, let’s look at the larger picture!
      • What is CAR-T cell therapy and why is it becoming more popular?
      • What can be a Major Concern for Laurus Labs in this case?
      • Why is Laurus Labs diversifying?

      The Story

      Laurus Labs

      Laurus Labs is a research-driven pharmaceutical company with four business lines — Generics APIs, Generics Finished Dosage Forms (FDFs), Synthesis/Ingredients and Biotechnology — that operates with globally benchmarked manufacturing capabilities and compliances.

      But this story isn’t about a blossoming Laurus Labs. This story is about a company that’s venturing into a new disruptive theory in the world of pharmaceutical business.

      So, let’s get going.

      How Laurus Labs is betting on CAR-T Cell Therapy, which is Revolutionizing Oncology!

      Recently, Laurus Labs has agreed to buy a 26.6% stake in ImmunoACT(on a fully diluted basis) for a cash considerationfor Rs.46 Cr., implying an enterprise value of INR1.7 billion.

      Additionally, senior management of Laurus Labs would also invest in ImmunoACT for a 5.64% stake for approximately Rs. 9.75 crore at same price and terms.

      Now what exactly ImmunoACT does?

      ImmunoACT is an advanced cell and gene therapy company which was founded in 2018 under the aegis of IIT Bombay incubator, Society for Innovation and Entrepreneurship (SINE) by Dr. Rahul Purwar.

      ImmunoACT has strong global partnerships including Dr. Carl June, pioneer of CART therapy as member of scientific advisory board. The company currently has portfolio of CAR-T therapy assets under various development stages for the treatment of multiple auto immune diseases and oncology indications.

      Following the completion of Laurus’ acquisition of a minority stake in ImmunoACT, the current promoters would continue to lead management and operations.

      ImmunoACT currently has four CAR-T cell molecules in development, one of which is in clinical trials.

      To be particular, HCAR-19 is being tested in clinical trials for Acute Lymphoblastic Leukemia (ALL) in adults and children, as well as Diffuse Large B-cell Lymphoma (DBCL).

      ImmunoACT had made no money in the last 2.5 yrs (i.e. in FY20, FY21, or 1HFY22.)

      But then why is Laurus Labs investing into Immuno ACT, let’s look at the larger picture!

      The rationale behind Laurus Labs’ investment in ImmunoACT is to strengthen Laurus Labs’ biologics business, which gives them access and entry into an emerging field of research.

      CAR-T therapy is a very promising treatment option that has seen a lot of success in the Western world. Currently, CAR-T therapy is not available in India, and this collaboration will assist the company in bringing this novel technology to Indian patients at a very low cost.

      According to a brokerage report, “CAR-T cell therapy is a new treatment for leukemia/lymphoma, with five commercialized products selling for USD1.5 billion worldwide.

      Given that ImmunoACT products are still in development, commercialization would depend on a positive clinical outcome. However, this is LAURUS’ entry into a possible CDMO opportunity in a new therapy space over the next 4-5 years.”

      What is CAR-T cell therapy and why is it becoming more popular?

      Laurus Labs

      CAR-T therapy has been hailed as a cure for cancer.

      To make things simple and easy, Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells.

      And the reason why it is so famous in the West is because of its success rate, which is around 30-40% for CAR T-cell therapy for long-term remission with no additional treatment, requires a very short treatment time and is safer than chemotherapy and stem cell transplants.

      CAR-T cell therapy is a promising new treatment for leukaemia and lymphoma and with increased acceptance and a strong pipeline of molecules in development. It clearly outperforms chemotherapy and stem cell transplant therapy.

      With various companies like Celgene (BMS), Gilead, Jansenn, and CARsegen pursuing CAR-T therapy clinical trials, the CAR-T Cell Therapy market is expected to grow significantly in the coming years.

      Laurus Labs

      To get more detailed analysis and Reports on Stocks, visit our Edge Report Section by subscribing to our StockEdge premium plans.

      What can be a Major Concern for Laurus Labs in this case?

      However, the picture looks rosy in the eyes of an investor considering the latest corporate announcement for the company, but we need to look at the risks of the business as well.

      The manufacturing complexity is a major reason for the therapy cost.

      The Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a cancer treatment breakthrough. Clinical trials conducted around the world have yielded promising results in patients nearing the end of their lives, particularly those with Acute Lymphocytic Leukemia.

      Despite the fact that this technology has a remarkable therapeutic potential for cancer patients, it is currently unavailable in India. Each patient’s CAR-T cell therapy costs between Rs.3 and 4 cr. As a result, the challenge is to develop this technology in a cost-effective manner and make it available to patients.

      Why is Laurus Labs diversifying?

      Dr. SatyanarayanaChava who is the CEO of Laurus Labs, wants to reduce its dependence on ARV APIs. 

      Currently, the revenues from ARV (formulations + API) are around two-third of total revenue. The management wants this to be around one-third by FY25.

      Due to commodity inflation, Laurus Labs has corrected in line with the pharmaceutical sector. Furthermore, the company reported the impact of antiretroviral active pharmaceutical ingredients destocking (APIs).

      However, as new growth levers emerge, it might be a good time to start looking at the stock from a long-term perspective. The company’s synthesis business is currently in transition.

      Laurus Labs is seeing a significant increase in fermentation opportunity, which is being supported by expansion plans. The management intends to expand fermentation capacity to ten lakh liters.

      The key risk to be aware of is China’s dependence on raw materials.

      In the fiscal quarter ended September 2021, the company’s sales increased 5.68% to Rs 1203.48 crore.

      However, its net profit fell 16.6% to Rs 201.90 crore, compared to Rs 242.27 crore in the previous quarter ended September 2020 and as of today’s date, this is Laurus Labs share price.

      Will the above mentioned acquisition, help the company’s stock reach new heights? That is something we will have to wait and see.

      Until then stay tuned for the next blog and keep watching this space for our midweek and weekend editions of ‘Trending Stocks”. And, share it with your friends & family.

      Tags: Dr. Satyanarayana ChavaLaurus Labs
      ShareTweetSend
      Subscribe On Telegram Subscribe On Telegram Subscribe On Telegram
      Previous Post

      How is Tata Motors ahead of its competitors in the Electric Vehicle theme in India?

      Next Post

      Black Friday Sale in the Market – Is your shopping list ready?

      StockEdge

      StockEdge

      StockEdge is a self-help Equity and Mutual Fund research tool. It empowers retail investors to identify investment opportunity with all the necessary data and analytics.

      Next Post
      Black Friday Sale in the Market – Is your shopping list ready?

      Black Friday Sale in the Market – Is your shopping list ready?

      How is ITC scaling up its FMCG business?

      How is ITC scaling up its FMCG business?

      What’s Trending: Neogen Chemicals, Vodafone Idea, and 3 other stocks

      What’s Trending: Neogen Chemicals, Vodafone Idea, and 3 other stocks

      Comments 4

      1. निलेश says:
        2 years ago

        Sir please provide this amazing knowledge in HINDI HINDI HINDI

        PLEASE SIR 🙏🙏

      2. Azeem Ansari says:
        2 years ago

        Thanks for this useful information ☺️

        • Dr Mansukh S Gatiwala says:
          2 years ago

          Very good information for investment purposes.

      3. Pradip Kumar Mondal says:
        1 year ago

        Thanks U for guiding us.

      Contact Us
      • Timing (Mon-Sat): 10 am to 7 pm
      • Sales: +919830994463
      • Support: +919830994402
      • Club Support: +916289906895
      • Affiliate: +917003567131
      Recent Posts
      All About NIFTY50, Components of NIFTY50, and How to Invest in it
      Simplify stock market analysis with Edge Reports | StockEdge
      Important Links
      • StockEdge.com
      • StockEdge Premium
      • - Quarterly Membership
      • - Annual Membership
      • StockEdge Analyst
      • StockEdge Club
      • Compare Plans
      An Initiative Of

      © 2023 Kredent InfoEdge Pvt Ltd.

      Facebook-f Twitter Instagram Linkedin-in Youtube Pinterest-p

      Get StockEdge App

      No Result
      View All Result
      • Home
      • Article Categories
        • Fundamental Analysis
        • Technical Analysis
        • Market Themes
        • StockEdge Tutorials
        • StockEdge Version Updates
      • Products
        • StockEdge Premium
        • StockEdge Pro
        • StockEdge Club
        • Compare Plans
      • Visit StockEdge.com

      © 2023 Kredent InfoEdge Pvt Ltd.

      ELM School

      Premium or Pro or Club?

      The market is back in decent shape and the good time to invest in stock is finally here.
      Become a smart investor with a stunning deal! Use code DEAL30 to get any plan at 30% flat discount

      GET YOUR PLAN